Ursolic Acid Enhances Myelin Repair in Adult Mice Brains and Stimulates Exhausted Oligodendrocyte Progenitors to Remyelinate

J Mol Neurosci. 2022 Oct;72(10):2081-2093. doi: 10.1007/s12031-022-02059-x. Epub 2022 Aug 17.

Abstract

In multiple sclerosis patients, long-term inflammation makes the oligodendrocyte progenitor cells (OPCs) exhausted; therefore, a new therapy that makes them responsive to insults to participate in remyelination is highly in demand. Here, we investigated the effect of ursolic acid (UA) on myelin repair after mid-term and long-term demyelination periods induced by 6 or 12 weeks of cuprizone treatment followed by 2 weeks of recovery with or without UA. Immunohistochemistry studies and myelin genes expression assessment were used to evaluate the myelination status of mouse corpora callosa and the cellular mechanisms of myelin repair. Results showed that UA significantly promoted recovery from myelin loss after discontinuing 6 or 12 weeks of cuprizone feeding, as measured by luxol fast blue (LFB), fluoroMyelin (FM), anti-myelin basic protein (MBP) staining, and oligodendrocyte progenitor cell counts. It led to reduced inflammation and gliosis as evaluated by glial fibrillary acidic protein (GFAP), Iba1, or other marker gene transcripts. Following long-term demyelination, gliosis and TNF-α were observed as potential players in lesion pathology, which were restored by UA. An increased IL-10 may contribute to UA anti-inflammatory effect and making responsive the exhausted OPCs. UA increased the number of new oligodendrocyte lineage cells and myelination. Our findings indicated that UA can enhance myelin repair after cuprizone challenge through the prevention of gliosis and increasing the newly generated myelin.

Keywords: Anti-inflammatory effect; Cuprizone demyelination; Multiple sclerosis; Myelin repair; Ursolic acid.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Corpus Callosum / pathology
  • Cuprizone / toxicity
  • Demyelinating Diseases* / chemically induced
  • Demyelinating Diseases* / drug therapy
  • Demyelinating Diseases* / metabolism
  • Disease Models, Animal
  • Glial Fibrillary Acidic Protein / metabolism
  • Gliosis
  • Inflammation / metabolism
  • Interleukin-10 / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Myelin Sheath / metabolism
  • Oligodendrocyte Precursor Cells* / metabolism
  • Oligodendroglia / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Ursolic Acid

Substances

  • Cuprizone
  • Glial Fibrillary Acidic Protein
  • Interleukin-10
  • Tumor Necrosis Factor-alpha
  • Anti-Inflammatory Agents